Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

With Gilead sprinting to a likely approval next year for its long-acting pre-exposure | With GSK girding for competition from ...

The executive director of the organization says gender inequality is one of the most important drivers of new infections, ...

As groundbreaking studies continue to reshape the human immunodeficiency virus (HIV) landscape, emerging therapies and ...

Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

Called pre-exposure prophylaxis (PrEP), this is ... it’s not yet approved for HIV prevention by medical regulators. The drug is currently priced at around US$42,000 (£31,600) a year if used ...

From oral PrEP, to injectables, rings, and implants, this year's HIV Research for Prevention conference was all about options ...

In the last 30 years, HIV rates have gone down, in large part because of the game-changing prescription drug pre-exposure ...

Lenacapavir for PrEP, injected just under the skin every ... which introduced the first long-acting HIV-prevention drugs but has not delivered a drug with the extended protection of lenacapavir.

The Biden-Harris administration has a historic opportunity to help end HIV. New, cutting-edge drugs that prevent HIV are ...

The second of two pivotal studies of a six-monthly HIV prevention injection containing the antiretroviral drug lenacapavir ...

Unlike oral PrEP treatments, which are taken daily ... for HIV/AIDS but does not yet have regulatory approval anywhere in the world as an HIV prevention drug. Once approved, producing enough ...